Table 2.
Plasma and urine levels of NP and RAAS biomarkers at baseline and Days 7 and 21 during LCZ696 treatment
| Biomarker | Baseline Na = 30 | Day 7 (LCZ696 100 mg bid) Na = 30 | Day 21 (LCZ696 200 mg bid) Na = 27 | ||
|---|---|---|---|---|---|
| Predose | Ratio‐to‐baseline (95% CI), P value | Predose | Ratio‐to‐baseline (95% CI), P value | ||
| Plasma NP biomarkers | |||||
| cGMP, nmol/L | 11.13 | 13.83 | 1.24 (1.06–1.45) P = 0.008 | 15.07 | 1.38 (1.16–1.65) P < 0.001 |
| ANP, pg/mL | 114.31 | 105.20 | 0.92 (0.80–1.05) P = 0.223 | 110.83 | 1.00 (0.80–1.26) P = 0.986 |
| Urine NP biomarkers | |||||
| cGMP, nmol | 937.96 | 1096.09 | 1.17 (0.97–1.40) P = 0.090 | 1180.57 | 1.22 (1.01–1.47) P = 0.040 |
| ANP, ng | 209.60 | 353.42 | 1.69 (1.40–2.03) P < 0.001 | 378.48 | 1.82 (1.54–2.17) P < 0.001 |
| Plasma RAAS biomarkers | |||||
| PRC, pg/mL | 9.92 | 42.64 | 4.30 (2.78–6.64) P < 0.001 | 34.11 | 3.50 (2.13–5.76) P < 0.001 |
| PRA, ng/mL/h | 0.69 | 2.70 | 3.94 (2.27–6.87) P < 0.001 | 1.64 | 2.27 (1.20–4.32) P = 0.014 |
ANP, atrial natriuretic peptide; bid, twice daily; cGMP, cyclic guanosine monophosphate; CI, confidence interval; NP, natriuretic peptide; PRA, plasma renin activity; PRC, plasma renin concentration; RAAS, renin–angiotensin–aldosterone system.
Data are presented as geometric means. The ratio‐to‐baseline after LCZ696 200 mg bid was calculated according to the baseline values for patients who completed the study.
a
Data for PRA are presented for 29 patients at baseline and on Day 7 and for 26 patients on Day 21.